MIDAZOLAM

Brand name:

• Zyamis®

Pharmaceutical company:

Clinect Pty Ltd

Condition/indication:
(therapeutic use)

• Generalised convulsive status epilepticus (GCSE)

PBAC Submission type:

Other matters (Category 3)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – November 2023

Related medicines:

• MIDAZOLAM
• MIDAZOLAM

Submission received for:

November 2023 PBAC meeting

Opportunity for consumer comment:

Open 26/07/2023 and close 20/09/2023 (see PBS Website)

PBAC meeting:

Held on 01/11/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

15/01/2024

Lodgement of required documentation:

06/02/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 03/06/2024

Status:

Finalised

Government processes:

Commenced on 07/06/2024

Medicine listed on the PBS:

01/08/2024 (see PBS schedule)

---